Expects first sales of Aphria-branded cannabis
in Germany in Q2 FY2021
LEAMINGTON, ON, Oct. 7, 2020 /CNW/ - Aphria Inc.
("Aphria" or the "Company") (TSX: APHA)
and (Nasdaq: APHA), a leading global cannabis company
inspiring and empowering the worldwide community to live their very
best life, today announced it has completed its first certified
European Union Good Manufacturing Practices ("EU GMP") shipment of
dried flower from its Aphria One EU GMP facility to its
wholly-owned German subsidiary, CC Pharma GmbH ("CC
Pharma"), a leading distributor of pharmaceutical products to
more than 13,000 pharmacies in Germany.
"Our first EU GMP shipment into Germany represents another significant
milestone for Aphria Inc., one that strengthens our position as a
leading cannabis company in Germany and in the European Union," said
Irwin D. Simon, Chief Executive
Officer, Aphria Inc. "We are leveraging our strong medical platform
and multi-faceted German strategy, which combines domestic
cultivation, import licenses and large distribution infrastructure,
to increase access to high-quality medical cannabis for patients
worldwide. We remain excited about future milestones, including the
completion of our cultivation facility in Neumünster, Germany, which we expect will be completed in
Q2 FY2021."
The German market is considered to be one of the most highly
sought-after developed medical cannabis markets in the
world. Aphria's German operations have been preparing for the
importation of EU-GMP certified cannabis from Canada, allowing for shipments to CC Pharma in
order to leverage CC Pharma's expansive in-country distribution
network.
In addition to today's announcement, other previously
announced strategic milestones for Aphria and its
wholly-owned subsidiaries in Germany include:
- Germany launched several
CBD-based wellness brands in Q1 FY2021, including:
-
- CannRelief brand, a line of cosmetic oils and creams as well as
supplements, that seek to deliver "the best from the cannabis plant
to impact the lives of our consumers for the better".
- Evoque brand, a line of natural sustainable products that help
optimize skin, which includes face creams and serums.
- CannaPet brand, a line of products that bring relaxation,
relief or recovery to pets.
We Have A Good Thing Growing.
About Aphria
Aphria Inc. is a leading global cannabis company striving to
inspire and empower the worldwide community to live their very best
life. Headquartered in Leamington,
Ontario – the greenhouse capital of Canada – Aphria Inc. has been setting the
standard for the low-cost production of high-quality cannabis at
scale, grown in the most natural conditions possible. Focusing on
untapped opportunities and backed by the latest technologies,
Aphria Inc. is committed to bringing breakthrough innovation to the
global cannabis market. The Company's portfolio of brands is
grounded in expertly-researched consumer insights designed to meet
the needs of every consumer segment. Rooted in our founders'
multi-generational expertise in commercial agriculture, Aphria Inc.
drives sustainable long-term shareholder value through a
diversified approach to innovation, strategic partnerships and
global expansion.
For more information, visit: aphriainc.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws and are expressly
qualified by this cautionary statement. Any statements that are
contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "potential", "believe",
"intend" or the negative of these terms and similar expressions.
Forward-looking statements in this news release include, but are
not limited to, statements with respect to the effects or
efficacy of medical cannabis products, timing of sales of
Aphria-branded cannabis in Germany
and the completion of the construction of Aphria's cultivation
facility in Neumünster, Germany.
Various assumptions were used in drawing the conclusions or making
the projections contained in the forward-looking statements
throughout this news release. Forward-looking statements are based
on the opinions, estimates and perception of trends of management
and its beliefs with respect to future events, as at the date the
statements are made, and are subject to a variety of risks and
uncertainties and other factors that could cause actual events or
results to differ materially from those projected in the
forward-looking statements. Forward-looking statements necessarily
involve known and unknown risks, including, without limitation,
risks associated with the COVID-19 pandemic; general economic
conditions; adverse industry events; marketing costs; loss of
markets; future legislative and regulatory developments involving
cannabis; inability to access sufficient capital from internal and
external sources, and/or inability to access sufficient capital on
favorable terms; the cannabis industry in Canada generally, income tax and regulatory
matters, including delays in the issuance of licenses, the sale and
distribution of vapes; the ability of Aphria to meet its liquidity
requirements to fund ongoing operations; the ability of Aphria to
implement its business strategies; competition; crop failure;
safety of derivative cannabis products; currency and interest rate
fluctuations.
Readers are cautioned that the foregoing list is not exhaustive
and should consider as other factors discussed under the heading
"Risk Factors" in Aphria's most recent Annual Information Form,
available on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov. Readers are further cautioned not to place undue
reliance on forward-looking statements as there can be no assurance
that the plans, intentions or expectations upon which they are
placed will occur. Such information, although considered reasonable
by management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those
anticipated.
The forward-looking statements included in this news release are
made as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities laws.
Neither TSX nor its Regulation Services Provider (as that term is
defined in the policies of Toronto Stock Exchange) accepts
responsibility for the adequacy or accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aphria-inc-announces-completion-of-first-eu-gmp-shipment-to-germany-301147525.html
SOURCE Aphria Inc.